{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T19:07:21Z","timestamp":1723316841577},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T00:00:00Z","timestamp":1601683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title \/>\n                  <jats:p>Both metachronous and synchronous tumors pose a diagnostic and clinical challenge, more so when one of the specimens demonstrates the rare neuroendocrine histology. We describe a patient with sarcoidosis who was treated for endometrial and ovarian neoplasm, recurred with two separate histologies (adenocarcinoma and high grade neuroendocrine), both associated with microsatellite instability (MSI)-high status. Targeted next-generation sequencing of tumor with synonymous somatic alterations pointed to a common ancestry of all three tumors and patient was successfully treated with a tailored immunotherapy regimen. Her sarcoidosis worsened only slightly, and immunotherapy did not need to be discontinued. This case highlights the importance of molecular testing for the optimal therapy of complex synchronous tumors and the need for communication between surgical and medical oncologists in patients with MSI-high cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key Points<\/jats:title>\n                  <jats:p>The case of a patient with a recurrent gynecological cancer presenting as microsatellite instability (MSI)-high endometrial adenocarcinoma and MSI-high neuroendocrine tumor is reported. This case demonstrated a common genetic lineage with good response to checkpoint inhibition without clinical worsening of autoimmune disease. This article adds to the literature, suggesting tumor evolution with neuroendocrine differentiation in some cancers, and argues that a molecular-based approach to treatment might achieve better understanding and possibly superior treatment outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/onco.13525","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T07:37:07Z","timestamp":1600414627000},"page":"90-96","source":"Crossref","is-referenced-by-count":3,"title":["Tumor Evolution in a Patient with Recurrent Endometrial Cancer and Synchronous Neuroendocrine Cancer and Response to Checkpoint Inhibitor Treatment"],"prefix":"10.1093","volume":"26","author":[{"given":"Nikolaos A.","family":"Trikalinos","sequence":"first","affiliation":[{"name":"Department of Medicine, Washington University in St. Louis, St Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deyali","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"Department of Pathology and Immunology, Washington University in St. Louis, St Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle","family":"Winter","sequence":"additional","affiliation":[{"name":"Department of Pathology and Immunology, Washington University in St. Louis, St Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Powell","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Washington University in St. Louis, St Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoyo","family":"Yano","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, Mayo Clinic College of Medicine, Scottsdale, Arizona, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,10,3]]},"reference":[{"key":"2021122511553393700_onco13525-bib-0001","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1053\/j.semdp.2013.06.007","article-title":"Neuroendocrine tumors of the gynecologic tract: Select topics","volume":"30","author":"Rouzbahman","year":"2013","journal-title":"Semin Diagn Pathol"},{"key":"2021122511553393700_onco13525-bib-0002","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122511553393700_onco13525-bib-0003","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/humu.22262","article-title":"Cancer risks for MLH1 and MSH2 mutation carriers","volume":"34","author":"Dowty","year":"2013","journal-title":"Hum Mutat"},{"key":"2021122511553393700_onco13525-bib-0004","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/ijc.29641","article-title":"Lynch syndrome and cervical cancer","volume":"137","author":"Antill","year":"2015","journal-title":"Int J Cancer"},{"key":"2021122511553393700_onco13525-bib-0005","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1158\/2159-8290.CD-19-0015","article-title":"Cellular plasticity in cancer","volume":"9","author":"Yuan","year":"2019","journal-title":"Cancer Discov"},{"key":"2021122511553393700_onco13525-bib-0006","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1172\/JCI44239","article-title":"The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression","volume":"120","author":"Sharma","year":"2010","journal-title":"J Clin Invest"},{"key":"2021122511553393700_onco13525-bib-0007","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aah4307","article-title":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer","volume":"355","author":"Mu","year":"2017","journal-title":"Science"},{"key":"2021122511553393700_onco13525-bib-0008","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1159\/000475527","article-title":"Digestive system mixed neuroendocrine-non-neuroendocrine neoplasms","volume":"105","author":"de Mestier","year":"2017","journal-title":"Neuroendocrinology"},{"key":"2021122511553393700_onco13525-bib-0009","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1245\/s10434-019-07268-0","article-title":"Genetic and immunohistochemical studies investigating the histogenesis of neuroendocrine and carcinomatous components of combined neuroendocrine carcinoma","volume":"26","author":"Iijima","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"2021122511553393700_onco13525-bib-0010","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3389\/fimmu.2018.00094","article-title":"Interleukin-6 and interferon-\u03b1 signaling via JAK1-STAT differentially regulate oncolytic versus cytoprotective antiviral states","volume":"9","author":"Danziger","year":"2018","journal-title":"Front Immunol"},{"key":"2021122511553393700_onco13525-bib-0011","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1158\/1535-7163.MCT-13-0605","article-title":"Pharmacologic suppression of JAK1\/2 by JAK1\/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation","volume":"13","author":"Gu","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"2021122511553393700_onco13525-bib-0012","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1530\/ERC-16-0443","article-title":"Prkar1a gene knockout in the pancreas leads to neuroendocrine tumorigenesis","volume":"24","author":"Saloustros","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"2021122511553393700_onco13525-bib-0013","doi-asserted-by":"crossref","first-page":"17550","DOI":"10.1038\/s41598-018-35592-0","article-title":"Crosstalk between SOX2 and cytokine signaling in endometrial carcinoma","volume":"8","author":"Lee","year":"2018","journal-title":"Sci Rep"},{"key":"2021122511553393700_onco13525-bib-0014","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1200\/JCO.2010.32.9979","article-title":"Testing women with endometrial cancer to detect Lynch syndrome","volume":"29","author":"Kwon","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122511553393700_onco13525-bib-0015","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/PAS.0000000000000633","article-title":"Neuroendocrine carcinoma of the endometrium: A clinicopathologic study of 25 cases","volume":"40","author":"Pocrnich","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"2021122511553393700_onco13525-bib-0016","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1634\/theoncologist.2016-0517","article-title":"Exceptional response to nivolumab and stereotactic body radiation therapy (SBRT) in neuroendocrine cervical carcinoma with high tumor mutational burden: Management considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center","volume":"22","author":"Sharabi","year":"2017","journal-title":"The Oncologist"},{"key":"2021122511553393700_onco13525-bib-0017","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion\u2013positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"2021122511553393700_onco13525-bib-0018","first-page":"1119","article-title":"Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer","volume":"32","author":"Franks","year":"2012","journal-title":"Anticancer Res"},{"key":"2021122511553393700_onco13525-bib-0019","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/aje\/kws375","article-title":"Use of azathioprine and the risk of cancer in inflammatory bowel disease","volume":"177","author":"Pasternak","year":"2013","journal-title":"Am J Epidemiol"},{"key":"2021122511553393700_onco13525-bib-0020","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1046\/j.1365-2036.2002.01297.x","article-title":"Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine","volume":"16","author":"Fraser","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"2021122511553393700_onco13525-bib-0021","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jtho.2018.04.031","article-title":"Sarcoidosis-like reactions induced by checkpoint inhibitors","volume":"13","author":"Gkiozos","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2021122511553393700_onco13525-bib-0022","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"2021122511553393700_onco13525-bib-0023","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"2021122511553393700_onco13525-bib-0024","doi-asserted-by":"crossref","first-page":"750","DOI":"10.6004\/jnccn.2019.7310","article-title":"Preexisting autoimmune disease: Implications for immune checkpoint inhibitor therapy in solid tumors","volume":"17","author":"Kennedy","year":"2019","journal-title":"J Natl Compr Canc Netw"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13525","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13525","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/2\/90\/41923207\/oncolo_26_2_90.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/2\/90\/41923207\/oncolo_26_2_90.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T11:59:17Z","timestamp":1640433557000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/2\/90\/6445347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,3]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,10,3]]},"published-print":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13525","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2,1]]},"published":{"date-parts":[[2020,10,3]]}}}